利什曼病化疗中的治疗转换：针对未满足治疗需求的独特方法。
Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.
作者信息
Shakya Nishi, Bajpai Preeti, Gupta Suman
机构信息
Division of Parasitology, Central Drug Research Institute, Chattar Manzil Palace, M.G. Road, Lucknow, 226001 UP India.
出版信息
J Parasit Dis. 2011 Oct;35(2):104-12. doi: 10.1007/s12639-011-0040-9. Epub 2011 May 20.
Abstract
Current drugs for the treatment of visceral leishmaniasis are inadequate. No novel compound is in the pipeline. Since economic returns on developing a new drug for neglected disease, leishmaniasis is so low that therapeutic switching represents the only realistic strategy. It refers to "alternative drug use" discoveries which differ from the original intent of the drug. Amphotericin B, paromomycin, miltefosine and many other drugs are very successful examples of "new drugs from old". This article reviews the discovery, growth and current status of these drugs and concluded that the potential of this approach (therapeutic switching) may use in the development of new antileishmanials in future also.
摘要
目前用于治疗内脏利什曼病的药物并不理想。尚无新型化合物处于研发阶段。由于研发治疗被忽视疾病利什曼病新药的经济回报很低，因此治疗转换是唯一现实的策略。它指的是与药物原始意图不同的“替代药物使用”发现。两性霉素B、巴龙霉素、米替福新和许多其他药物都是“旧药新用”的非常成功的例子。本文回顾了这些药物的发现、发展和现状，并得出结论，这种方法（治疗转换）在未来开发新的抗利什曼病药物方面也可能具有潜力。
相似文献
1
Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.
J Parasit Dis. 2011 Oct;35(2):104-12. doi: 10.1007/s12639-011-0040-9. Epub 2011 May 20.
2
Current scenario of drug development for leishmaniasis.
Indian J Med Res. 2006 Mar;123(3):399-410.
3
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Lancet. 2011 Feb 5;377(9764):477-86. doi: 10.1016/S0140-6736(10)62050-8. Epub 2011 Jan 20.
4
Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
PLoS Negl Trop Dis. 2017 May 15;11(5):e0005620. doi: 10.1371/journal.pntd.0005620. eCollection 2017 May.
5
Recent strategies for the chemotherapy of visceral leishmaniasis.
Curr Opin Infect Dis. 1999 Dec;12(6):559-64. doi: 10.1097/00001432-199912000-00006.
6
The treatment of visceral leishmaniasis: safety and efficacy.
JNMA J Nepal Med Assoc. 2013 Oct-Dec;52(192):645-51.
7
In vitro interaction between paromomycin sulphate and four drugs with leishmanicidal activity against three New World Leishmania species.
J Antimicrob Chemother. 2014 Jan;69(1):150-4. doi: 10.1093/jac/dkt318. Epub 2013 Aug 22.
8
Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Acta Trop. 2011 Aug;119(2-3):188-93. doi: 10.1016/j.actatropica.2011.05.017. Epub 2011 Jun 7.
9
The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
Expert Opin Drug Discov. 2020 Jun;15(6):647-658. doi: 10.1080/17460441.2020.1743674. Epub 2020 Mar 23.
10
Comparison of Resistance of Wild İsolates, Which are Resistant to Pentavalent Antimonial Compounds, Against Drugs Used in the Treatment of Leishmaniasis.
Turkiye Parazitol Derg. 2020 Mar 20;44(1):12-16. doi: 10.4274/tpd.galenos.2019.6661.
引用本文的文献
1
Advances in Cysteine Protease B Inhibitors for Leishmaniasis Treatment.
Curr Drug Targets. 2025;26(2):88-108. doi: 10.2174/0113894501324437240919064715.
2
Unravelling the myth surrounding sterol biosynthesis as plausible target for drug design against leishmaniasis.
J Parasit Dis. 2021 Dec;45(4):1152-1171. doi: 10.1007/s12639-021-01390-1. Epub 2021 Apr 24.
3
Bioprospecting marine actinomycetes for antileishmanial drugs: current perspectives and future prospects.
Heliyon. 2021 Aug 2;7(8):e07710. doi: 10.1016/j.heliyon.2021.e07710. eCollection 2021 Aug.
4
Infectivity and Drug Susceptibility Profiling of Different -Host Cell Combinations.
Pathogens. 2020 May 20;9(5):393. doi: 10.3390/pathogens9050393.
5
Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB.
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:70-79. doi: 10.1016/j.ijpddr.2019.10.004. Epub 2019 Oct 22.
6
Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.
Sci Rep. 2019 Jan 24;9(1):438. doi: 10.1038/s41598-018-36944-6.
7
Evaluation of a new set of recombinant antigens for the serological diagnosis of human and canine visceral leishmaniasis.
PLoS One. 2017 Sep 28;12(9):e0184867. doi: 10.1371/journal.pone.0184867. eCollection 2017.
8
The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery.
PLoS Negl Trop Dis. 2017 Jun 8;11(6):e0005480. doi: 10.1371/journal.pntd.0005480. eCollection 2017 Jun.
9
Therapeutic switching: from antidermatophytic essential oils to new leishmanicidal products.
Mem Inst Oswaldo Cruz. 2015 Feb;110(1):106-13. doi: 10.1590/0074-02760140332. Epub 2015 Feb 13.
10
Development, characterization, and in vitro biological performance of fluconazole-loaded microemulsions for the topical treatment of cutaneous leishmaniasis.
Biomed Res Int. 2015;2015:396894. doi: 10.1155/2015/396894. Epub 2015 Jan 12.
本文引用的文献
1
Combination therapy for visceral leishmaniasis.
Lancet Infect Dis. 2010 Mar;10(3):184-94. doi: 10.1016/S1473-3099(10)70011-6.
2
Drug resistance in visceral leishmaniasis.
J Biomed Biotechnol. 2010;2010:617521. doi: 10.1155/2010/617521. Epub 2009 Nov 1.
3
Developments in the treatment of visceral leishmaniasis.
Expert Opin Emerg Drugs. 2009 Sep;14(3):395-410. doi: 10.1517/14728210903153862.
4
Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
J Immunol. 2009 Jun 1;182(11):7146-54. doi: 10.4049/jimmunol.0803859.
5
Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
Am J Trop Med Hyg. 2009 Apr;80(4):580-2.
6
Visceral leishmaniasis: advances in treatment.
Recent Pat Antiinfect Drug Discov. 2008 Nov;3(3):192-8. doi: 10.2174/157489108786242341.
7
Development of new antileishmanial drugs--current knowledge and future prospects.
J Enzyme Inhib Med Chem. 2008 Oct;23(5):708-18. doi: 10.1080/14756360802208137.
8
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.
Antimicrob Agents Chemother. 2008 Oct;52(10):3573-9. doi: 10.1128/AAC.00587-08. Epub 2008 Jul 21.
9
Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.
Ther Clin Risk Manag. 2007 Oct;3(5):733-40.
10
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Int J Antimicrob Agents. 2007 Sep;30(3):229-35. doi: 10.1016/j.ijantimicag.2007.05.007. Epub 2007 Jul 12.
Zotero 插件